Study: NCT01871766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Dosage and route of administration:~* \< 1 year of age=0.025 mg/kg intravenously (IV)~* \> 1 year and \< 3 years= 0.05 mg/kg IV~* ≥ 3 years=1.5 mg/m\^2 IV. Maximum dose 2 mg in all participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Dosage and route of administration:~* \< 1 year of age=0.025 mg/kg intravenously (IV)~* \> 1 year and \< 3 years= 0.05 mg/kg IV~* ≥ 3 years=1.5 mg/m\^2 IV. Maximum dose 2 mg in all participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Dosage and route of administration:~* \< 1 year of age=0.025 mg/kg intravenously (IV)~* \> 1 year and \< 3 years= 0.05 mg/kg IV~* ≥ 3 years=1.5 mg/m\^2 IV. Maximum dose 2 mg in all participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Dosage and route of administration:~* \< 1 year of age=0.025 mg/kg intravenously (IV)~* \> 1 year and \< 3 years= 0.05 mg/kg IV~* ≥ 3 years=1.5 mg/m\^2 IV. Maximum dose 2 mg in all participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Dosage and route of administration:~* \< 1 year=0.025 mg/kg IV push~* ≥ 1 year=0.045 mg/kg IV push over 1 to 5 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Dosage and route of administration:~* \< 1 year=0.025 mg/kg IV push~* ≥ 1 year=0.045 mg/kg IV push over 1 to 5 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Dosage and route of administration:~* \< 1 year=0.025 mg/kg IV push~* ≥ 1 year=0.045 mg/kg IV push over 1 to 5 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Dosage and route of administration:~* \< 1 year=0.025 mg/kg IV push~* ≥ 1 year=0.045 mg/kg IV push over 1 to 5 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Dosage and route of administration:~During VAC chemotherapy:~* \< 3 years of age = 40 mg/kg IV~* ≥ 3 years of age = 1200 mg/m\^2 IV, with MESNA.~During maintenance for intermediate-risk participants:~* oral cyclophosphamide 50 mg/m\^2/dose/day (liquid or tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Dosage and route of administration:~During VAC chemotherapy:~* \< 3 years of age = 40 mg/kg IV~* ≥ 3 years of age = 1200 mg/m\^2 IV, with MESNA.~During maintenance for intermediate-risk participants:~* oral cyclophosphamide 50 mg/m\^2/dose/day (liquid or tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Dosage and route of administration:~During VAC chemotherapy:~* \< 3 years of age = 40 mg/kg IV~* ≥ 3 years of age = 1200 mg/m\^2 IV, with MESNA.~During maintenance for intermediate-risk participants:~* oral cyclophosphamide 50 mg/m\^2/dose/day (liquid or tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Dosage and route of administration:~During VAC chemotherapy:~* \< 3 years of age = 40 mg/kg IV~* ≥ 3 years of age = 1200 mg/m\^2 IV, with MESNA.~During maintenance for intermediate-risk participants:~* oral cyclophosphamide 50 mg/m\^2/dose/day (liquid or tablet)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Surgery will be performed for the primary site tumor with the goal of removing tumor cells while maintaining function in the organ or adjacent organs involved.